SS Innovations International Inc. filings document a Nasdaq-listed surgical robotics issuer and its formal disclosures around the SSi Mantra platform. Recent Current Reports on Form 8-K record product and regulatory updates, telesurgery announcements, conference-related disclosures, financial-results releases and Regulation FD communications.
The filing record also covers capital structure events, including an unregistered private placement of common stock, and identifies the company’s common stock as registered on Nasdaq under SSII. Annual-report and current-report disclosures provide formal context for operating results, product development, clinical and regulatory timelines, forward-looking statements, and the company’s subsidiary-based reporting perimeter.
SS Innovations International, Inc. (SSII) furnished an updated November 2025 Company Presentation under Item 7.01 (Regulation FD Disclosure). The presentation is attached as Exhibit 99.1.
The materials are deemed “furnished,” not “filed,” which limits their applicability under Section 18 of the Exchange Act and they are not incorporated by reference into other filings. The notice includes customary forward‑looking statements language, highlighting that actual results may differ due to risks described in the company’s periodic reports.
SS Innovations International (SSII) reported a technology milestone. The company announced the successful completion of the first telesurgery performed using its SSi Mantra Tele Surgeon Console. The system is a compact, self-contained, chair-based version of the larger SSi Mantra command center, designed for portability, smaller spaces, and telesurgery from varied settings, including physician offices.
The announcement was made on November 6, 2025, and a detailed press release was furnished as Exhibit 99.1.
SS Innovations International (SSII) furnished a press release discussing results of operations for the three and nine month periods ended September 30, 2025. The company made the disclosure under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure), and attached the press release as Exhibit 99.1.
The information in Items 2.02 and 7.01, and Exhibit 99.1, is deemed “furnished” rather than “filed,” and is not subject to Section 18 liabilities or incorporated by reference into other filings.
SS Innovations International (SSII) filed its quarterly report and reported strong top-line growth with continued losses. Q3 revenue was $12.83M, up from $4.39M a year ago, driven by system sales. Gross profit rose to $6.16M from $2.32M. The company posted a Q3 net loss of $3.72M and a year‑to‑date net loss of $9.66M, an improvement from $17.23M in the prior‑year period.
As of September 30, 2025, total cash, cash equivalents and restricted cash were $12.04M; current cash and cash equivalents were $5.68M. Working capital showed a surplus of $27.24M. Operating cash outflow was $17.02M year‑to‑date, partly offset by $24.79M of net financing inflows, including issuance of $28.0M of one‑year 7% convertible notes and subsequent conversions totaling 21.86M shares. Inventory increased to $20.04M from $10.21M to support demand.
The company disclosed “substantial doubt” about its ability to continue as a going concern, citing ongoing losses and reliance on related‑party funding even after its April 2025 Nasdaq uplisting. During Q3, it sold 28 surgical robotic systems (55 year‑to‑date). Revenue was concentrated in India, which represented 94% of Q3 sales.
SS Innovations International (SSII) announced management participation in two investor conferences. The company will join the UBS Global Healthcare Conference in Palm Beach Gardens, FL on November 11, 2025, and the Stifel 2025 Healthcare Conference in New York, NY on November 12, 2025. The Stifel event includes a group presentation at 4:40 p.m. Eastern Time.
A live webcast and replay of the Stifel presentation will be available on the company’s website at https://ssinnovations.com/investor-overview/. The disclosure is provided under Item 7.01 (Regulation FD) and is deemed “furnished,” not “filed.”
SS Innovations International (SSII) furnished an updated October 2025 Company Presentation under Item 7.01 (Regulation FD). The presentation is attached as Exhibit 99.1 and is intended for communications with shareholders and the investment community.
The information is deemed “furnished” rather than “filed,” meaning it is not subject to Section 18 liability and is not incorporated by reference into other Securities Act or Exchange Act filings. The report also includes standard forward‑looking statements cautionary language.
Amar Naveen Kumar is reported as an officer (CFO) and director of SS Innovations International, Inc. (SSII). The Form 3 shows no beneficial ownership of the issuer's common stock and no derivative holdings are disclosed. The filing provides the reporting person's address in Fort Lauderdale, FL and includes the required signature attestation.
SS Innovations International, Inc. reported that it has successfully completed a human factors validation study for its SSi Mantra surgical robotic system at Johns Hopkins Hospital in September 2025. The company also stated that it anticipates submitting a 510(k) premarket notification to the U.S. Food and Drug Administration for SSi Mantra for multiple specialty indications in the fourth quarter of 2025. These steps mark progress in the company’s effort to bring its surgical robotic system to the U.S. market, although regulatory clearance has not yet been obtained.
SS Innovations International, Inc. appointed Naveen Kumar Amar as its new Chief Financial Officer, effective September 24, 2025. The change was disclosed in a current report and accompanied by a press release and a formal employment agreement.
Mr. Amar, age 49, brings over 27 years of global corporate finance experience across accounting, audits, capital raising, compliance, taxation, mergers and acquisitions and investor relations. His background includes senior roles at SpiceExpress (the cargo unit of SpiceJet Ltd.), Munchado India, MSD Wellcome Trust Hilleman Laboratories, EDirect Proprietary Ltd. and GE India, and he is both a Chartered Accountant and Company Secretary in India.
The Company and Mr. Amar entered into a five-year employment agreement that provides for a base annual salary of approximately US$163,000, based on current Indian rupee to U.S. dollar exchange rates, and includes customary confidentiality, intellectual property, non-competition and non-solicitation provisions.
SS Innovations International, Inc. reported that the world’s first pediatric pyeloplasty telesurgery was successfully performed using its SSi Mantra surgical robotic system. This means a complex kidney-related procedure in a child was carried out remotely with the help of the company’s robot-assisted platform, highlighting a significant technical and clinical milestone for its technology. The company furnished a press release with additional details as an exhibit to this report.